February 28th, 2024

inSoma Appoints Head of Regulatory Affairs

inSoma is pleased to welcome Thalia Charles as its Head of Regulatory Affairs. In this role, Ms. Charles will support the advancement of inSoma’s regenerative reconstruction platform, Fractomer™, into clinical evaluation for its potential as a safe and natural option for patients opting for reconstruction. She brings 20 years’ experience steering medical devices through agency oversight to market, and deep expertise in the reconstruction and augmentation regulatory environment. Ms. Charles joins inSoma from Establishment Labs where she served as Senior Director of Global Regulatory Affairs. Prior to Establishment Labs, she served as Director of Regulatory Affairs for TransMedics, Inc. Across her career, she has successfully navigated the regulatory landscape for products including donor organ preservation systems, cancer screening products, and coagulopathy testing. She received her Master’s in developmental psychobiology from Indiana University–Bloomington and her B.S. in psychology from Brown University.

January 4th, 2024

Dr. Juliana Blum Joins inSoma Board of Directors

inSoma is pleased to announce the addition of Juliana Blum, Ph.D., to its Board of Directors. Dr. Blum is an expert in residence for NCBiotech and has spent over 20 years combining her scientific technical expertise with bioengineered regenerative tissue development. As a co-founder and former Executive Vice President of Corporate Development of Humacyte, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at a commercial scale, Dr. Blum brings deep expertise in building a novel biotechnology platform and advancing the company through late-stage clinical development. She received her doctorate in Molecular Biology from Loyola University Chicago with a focus in cardiovascular gene therapy and her bachelors’ degree at Carthage College in Wisconsin.

November 1st, 2023

inSoma Raises $2.5M in Seed Round

inSoma today announced it has raised $2.5 million in 2023 as part of a seed round. The raise builds on an initial pre-seed round raised in 2020, as well as the continued grant funding that inSoma has received from the NIH and NSF, and deepens the financial foundation from which to advance the development of a portfolio of injectable materials designed to mimic human tissue that can be used to rebuild a person’s tissue more safely and accurately, without the need for synthetic implants or fillers.